Cardurion Pharmaceuticals Secures $260 Million Series B to Advance Cardiovascular Drug Pipeline
Cardurion Pharmaceuticals, a pioneering biotechnology firm specializing in innovative therapies for cardiovascular diseases, has announced the successful completion of a $260 million Series B financing round. Led by Ascenta Capital and supported by a consortium of esteemed investors including NEA, GV, and Fidelity Management & Research Company, this substantial funding underscores Cardurion’s commitment to advancing…